32: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 2

Discover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars.

Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale.

Key Insights:

1. Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible.
2. Bridge the Gap between academia and industry in glycoengineering and thus ensure a smoother integration of groundbreaking glycoengineering technologies into the industrial landscape.
3. Gain valuable insights into the challenges and triumphs of transitioning from pure science to entrepreneurship, offering aspiring scientists a roadmap to navigate the unknown.

Connect with Thomas Rexer:

LinkedIn: https://www.linkedin.com/in/thomas-rexer

Website: www.eversyn.de

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show